# Gen AI in Pharma: Which Use Cases Should You Start With?

> Choose a first pharma Gen AI use case by error consequence, review effort and measurable value. A practical decision guide for CIOs and delivery heads.

- AI-drafted | Reviewed & approved by: [Muhammed Shakir](https://www.linkedin.com/in/muhammed-shakir-gen-ai-trainings-and-consulting), Founder · Architect, engineer and trainer
- Published: 2026-11-01
- Last updated: 2026-11-01
- Topic: AI by Industry
- Written for: CIOs, CTOs and delivery heads
- Web page: https://infomovertech.com/articles/gen-ai-in-pharma-first-use-cases

**At a glance:** Start with a bounded, read-only assistant for internal operational information, using an approved document set and a named reviewer. Choose work where mistakes are detectable and recoverable. Measure time saved after checking and correction, and keep patient, batch-release and regulatory decisions outside the first pilot.

## The short answer

Start with a bounded, read-only assistant that helps staff find internal operational information from an approved document set, with a named person checking the answer before acting. Choose work where a mistake is detectable and recoverable, and measure time saved after review and correction. Keep patient, batch-release and regulatory decisions outside this first pilot.

---

## Choose by the consequence of an error

For a pharma CTO, the first investment should answer a practical question: can this team reduce a recurring burden without creating a harder problem for quality, security or the people reviewing the output?

A convincing demonstration does not settle that question. An assistant that finds an IT support guide and one that interprets a manufacturing instruction may look similar on screen. The consequences of a wrong answer differ sharply.

[EMA's September 2024 reflection paper](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf) relates AI risk to its context of use and its influence on decisions. The [FDA's January 2025 draft guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological) similarly proposes assessing credibility for a particular use in drug regulatory decision-making; it is a draft with non-binding recommendations.

Write down what a user will do with the answer before choosing a model or buying a licence. Have your quality and regulatory owners assess the actual workflow against the markets and activities involved. The ordering below is a recommendation for a first investment, rather than a regulatory classification.

For your first investment, work that touches GxP—the good-practice requirements relevant to regulated activities—can add validation, documentation and quality-review effort before you have evidence of value. Budget for that work and the time it takes to reach a decision. If a wrong answer reaches a manufacturing instruction or regulatory record, the business may also face investigation, corrective work and disruption. Start outside that boundary to measure the team's ability to deliver useful, checked answers before taking on those responsibilities.

---

## Three candidates, in the order to examine them

| Candidate | Useful first boundary | Main business risk | Recommendation |
|---|---|---|---|
| Internal operational knowledge search | Current IT help guides and general administrative policies, accessible to the user | Wrong guidance, confidential information reaching the wrong person, or stale documents | Examine first if the information is genuinely outside regulated work and easy to verify |
| Public-literature summaries for exploratory reading | A defined set of public papers, with links to the original passages | Missing qualifications or unsupported conclusions that misdirect subsequent work | Consider next, with an expert checking completeness and meaning |
| Drafting or comparing controlled documents | Proposed text or differences shown to a qualified reviewer; no change to the approved record | An omitted condition or plausible alteration surviving review | Treat as a separate, more demanding proposal with quality ownership |

For the first candidate, choose one recurring question family: for example, helping staff locate the correct IT support route and the current access-request instructions. In a pharma business, other candidates could be corporate travel guidance for staff moving between research sites, or conference-attendance and expense policies for scientific staff. Ask the document and quality owners to confirm those particular workflows sit outside GxP; exclude laboratory access, sample transport and regulated training decisions. These examples concern general administration, rather than how research or manufacturing work is performed.

Exclude manufacturing procedures, laboratory instructions, product quality records and safety reporting. If a question reaches one of those areas, route the user to its established process.

Do not assume every administrative task is harmless. An access guide can still expose sensitive information or send someone down the wrong approval path. Keep the pilot read-only and require the user to open and check the cited guide.

Public-literature summarisation is a possible starting point when an expert can readily check the selected papers. It becomes a different proposal when someone relies on it for clinical evidence, safety decisions or submission content. Define that boundary explicitly.

Document drafting deserves particular care. EMA's paper calls for close human supervision and quality review of AI-generated medicinal product information before regulatory submission. A document workflow needs a reviewer with the expertise, source material and time to detect omissions; a final approval button alone is weak evidence of control.

For this first pilot, exclude patient-specific advice, batch-release decisions and autonomous safety-case processing. Those exclusions keep this investment focused; they do not imply AI can never support those activities.

---

## Put the boundary in the system

A misleading answer can send staff through the wrong process; an over-shared answer can expose confidential material. Make the boundary enforceable so you can investigate and contain either failure. An instruction asking the assistant to be careful does not establish who can retrieve a file, which version is current or whether the answer reaches another system.

![Approved documents feed a read-only answer with sources; a person checks it before taking action through the existing process. The assistant cannot update business records.](https://infomover-public-content.s3.ap-south-1.amazonaws.com/prod/infomover/gen-ai-in-pharma-first-use-cases/pilot-boundary.svg)

*Keep the assistant's output separate from business action: a checked answer informs a person using the existing process.*

For the operational knowledge pilot, ask the team to demonstrate these controls:

- **A defined source set.** A document owner lists what is included, its version and review date, and what has been excluded. Superseded material is removed from retrieval when the source changes.
- **Permissions before retrieval.** The system filters documents using the user's access rights before sending content to the model. Test with two users who should see different material.
- **Evidence beside the answer.** Show the source passage and document version. The reviewer checks that the passage supports the answer, rather than merely confirming that a link exists.
- **A useful refusal.** When the answer is absent, conflicting or outside scope, return the relevant human route. Test questions whose answers are deliberately missing.
- **No authority to act.** The assistant cannot approve access, change a controlled document, update a quality record or send an external response. Users continue through the existing approval process.

Keep patient data and live quality records out of this pilot dataset. Before using internal material, review provider terms, retention, processing location and who can inspect prompts and logs. Choose logging that supports investigation without unnecessarily duplicating sensitive content.

Read-only access limits what the assistant can change directly. It still leaves a person able to act on a misleading answer, which is why source checking and clear exclusions matter.

---

## Measure the task after checking and correction

The investment earns its place when it makes completed work better or cheaper. Time to generate an answer is only one part of that calculation.

Take a representative sample of real questions and record the manual process: finding the source, reading it, checking the answer and resolving exceptions. Compare it with the assisted process using equivalent tasks and the same acceptance standard. Use questions the team did not use to tune the assistant, including stale documents, missing answers, conflicting guidance and restricted content.

Track accepted answers, unsupported claims, wrong-version answers, access failures and total staff time. Count the effort spent correcting or abandoning a response. Also check whether the assistant returned the right source when it appropriately declined to answer.

Consider this **hypothetical illustration, not a forecast or customer result**:

| Work per question | Manual process | Assisted process |
|---|---:|---:|
| Find material and prepare an answer | 12 minutes | 3 minutes |
| Check sources and correct the answer | 3 minutes | 7 minutes |
| Total | 15 minutes | 10 minutes |

At 200 comparable questions a month, the difference is 1,000 staff minutes, or about 16.7 hours. If assisted checking and correction instead takes 13 minutes, its total reaches 16 minutes and the saving disappears. Include failed attempts and exception handling in those averages.

Convert the measured time difference into value using your own staff-cost assumptions, then subtract operating, support, document-maintenance and evaluation costs. Time released is capacity; it becomes a financial saving only if the business can use or remove that cost. The broader [Gen AI application cost guide](/articles/gen-ai-application-total-cost) explains the delivery and operating costs to include.

---

## What this means for you: fund one bounded decision

Approve a pilot charter with a business owner, a document owner, a technical owner and quality involvement in the scope decision. Give it one question family, an authorised user group, a fixed spending limit and an end date. Keep the existing manual route available.

Agree the acceptance criteria before the pilot begins. For this operational assistant, a useful starting proposal is:

- No unauthorised document disclosure in the access tests, with any observed disclosure stopping use pending investigation.
- No unsupported instruction accepted in the evaluation sample; report the sample size and review method alongside the result.
- Lower total time per accepted task, including checking, correction and exceptions, at a monthly operating cost the business accepts.
- A demonstrated way to remove a source, disable the assistant and return users to the manual route.

Passing a finite sample does not prove that future answers will always be correct. Use the evidence to decide whether to continue within the tested boundary, and keep monitoring errors after rollout. Reassess when the source set, users, model or intended use changes. Expansion into regulated work needs its own assessment.

Compare an existing enterprise product with a narrow custom application against the same question set and controls. A product may reduce delivery effort, but ask the vendor to demonstrate permissions, source traceability and refusal behaviour on your material. Custom development is worth considering when those requirements cannot be met; retain internal ownership of acceptance and operations either way.

For the wider launch decision, use the [five production-readiness gates](/articles/gen-ai-proof-of-concept-to-production). This pilot's result should be a measured choice to continue, change scope or stop.

---

## Questions to ask before funding the first pharma AI pilot

1. Which recurring task will improve, and what does completing it cost today?
2. Who has assessed whether its intended use affects product quality, patient safety or regulatory evidence?
3. Which documents and users are in scope, and how will the system enforce that boundary?
4. Can the reviewer detect a wrong answer from the evidence provided, within the time budgeted?
5. What result would make us stop, and who can disable the assistant?
6. What evidence would justify expansion beyond the first question family?

If those answers need work, a consulting engagement can start with the use-case boundary, document assessment and acceptance criteria. [Discuss your project](/contact).

## Related

- Consulting: [Enterprise AI Adoption](https://infomovertech.com/services/enterprise-ai-adoption), [Gen AI Architecture & Engineering](https://infomovertech.com/services/ai-engineering)